Finland· FI-REL-REL55123
Jyseleca
A filgotinib product containing filgotinib maleate, registered in Finland by ALFASIGMA S.p.A.. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Filgotinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L04AF04 (filgotinib), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 6 of them publish a price we can compare per daily dose
Filgotinib · ATC L04AF04
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Filgotinib maleate
- Manufacturer
- ALFASIGMA S.p.A.
- Country
- Finland (FI)
- ATC code
- L04AF04
- ATC class
- Filgotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa09551530EUR 890.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Filgotinib in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJYSELECAAlfasigma S.p.A., Bologna
- SpainJYSELECA 200 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAlfasigma S.P.A.
- FranceJYSELECA 200 mg, comprimé pelliculéALFASIGMA (ITALIE)
- IrelandJyseleca 200 mg film-coated tabletsAlfasigma S.p.A
- IcelandJyselecaAlfaSigma S.p.A.
- NetherlandsJyseleca 200 mg, filmomhulde tablettenAlfasigma S.p.A.
- NorwayJyselecaAlfasigma S.p.A
- PolandJyselecaAlfasigma S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jyseleca
- Liechtenstein · Jyseleca
- Norway · Jyseleca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cd2ffd28-d5af-4a55-bd31-7832eb5cd2e0 GET /v1/drugs/cd2ffd28-d5af-4a55-bd31-7832eb5cd2e0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "0.2",
"form": "tabletti, kalvopäällysteinen",
"route": "Suun kautta",
"ddd_unit": "g",
"strength": "200 mg",
"atc_label": "filgotinibi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/20/1480/003-004",
"fimea_rel_id": "REL55123",
"authorised_at": "2020-09-24"
}See everything about filgotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.